Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director · Chief Executive Officer | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,485 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 528 · Balance 35,485 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 43,803 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 43,803 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $137.15 | $41,145.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 30 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,559 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 767 | $137.14 | $105,186.38 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 29 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,859 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 249 | $137.13 | $34,145.37 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 28 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 676 | $137.12 | $92,693.12 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 27 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,875 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.11 | $13,711.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 26 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,551 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 134 | $137.10 | $18,371.40 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 25 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,651 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 201 | $137.09 | $27,555.09 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 24 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,785 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.08 | $13,708.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 23 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,986 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.07 | $13,706.50 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 22 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,086 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.06 | $13,705.50 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 21 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,186 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,314 | $137.05 | $180,083.70 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 20 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,286 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 52 | $137.03 | $7,125.56 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 19 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 51 | $137.03 | $6,988.28 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 18 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,652 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 193 | $137.02 | $26,444.86 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 17 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,703 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 791 | $137.01 | $108,374.91 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 16 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,896 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 77 | $137.01 | $10,549.39 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 15 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,687 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 713 | $137.00 | $97,681.00 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 14 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,764 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 503 | $136.99 | $68,905.97 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 13 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,477 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 65 | $136.99 | $8,904.03 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 12 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,980 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 192 | $136.98 | $26,300.16 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 11 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,045 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 177 | $136.98 | $24,244.58 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 10 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,237 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 195 | $136.97 | $26,709.15 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 9 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,414 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 208 | $136.96 | $28,487.68 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 8 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,609 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 350 | $136.95 | $47,932.50 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 7 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,817 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 401 | $136.94 | $54,912.94 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 6 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,167 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 96 | $136.93 | $13,145.28 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 5 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,568 Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,204 | $109.34 | $350,325.36 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,492 | $88.05 | $307,470.60 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,675 | $73.70 | $123,447.50 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,233 | $76.67 | $94,534.11 |
DisclosureSEC source: 0001127602-19-032767 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired by the Reporting Person pursuant to an exempt transaction under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 14:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 125 | $140.71 | $17,588.75 |
DisclosureSEC source: 0001127602-19-008794 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,045 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 152 | $145.31 | $22,087.12 |
DisclosureSEC source: 0001127602-19-008794 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,170 Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 19:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $144.67 | $46,583.74 |
DisclosureSEC source: 0001127602-19-008320 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,322 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 19:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 316 | $144.67 | $45,715.72 |
DisclosureSEC source: 0001127602-19-008320 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,644 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 11,832 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-19-008320 · form4.xml · derivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,832 Underlying: Common Stock · 11,832 shares Expires 2024-02-22 F2 · derivative.exercise_date: Stock options vest equally over four (4) years beginning one year from date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008320 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,960 F1 · security: Consists of 2,775 unvested restricted stock units that vest as follows: 693 shares vest one (1) year from the date of issuance, 694 shares vest two (2) years from the date of issuance, 694 shares vest three (3) years from the date of issuance, and 694 shares vest four (4) years from the date of issuance. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 18:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,375 | $119.39 | $164,161.25 |
DisclosureSEC source: 0001127602-19-003328 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,185 Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 18:02 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-003328 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,560 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 26, 2016. Read SEC document |
| July 17, 2018 Filed Jul 18, 2018 18:32 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,978 | $119.90 | $476,962.20 |
DisclosureSEC source: 0001127602-18-023473 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,999 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,492 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · derivative · entry 29 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,477 Underlying: Common Stock · 3,492 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,675 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · derivative · entry 28 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 1,675 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,233 | $0.00 Strike: $76.67 | $0.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · derivative · entry 27 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233 Underlying: Common Stock · 1,233 shares Expires 2020-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 913 | $0.00 Strike: $59.41 | $0.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · derivative · entry 26 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 913 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $109.21 | $21,842.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 25 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,977 Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $109.20 | $43,680.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 24 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,177 Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $109.18 | $10,917.50 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 23 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,577 Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,300 | $109.16 | $141,908.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 22 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,677 Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 800 | $109.15 | $87,320.00 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 21 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 900 | $109.15 | $98,230.50 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 20 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,777 Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $109.13 | $32,737.50 |
DisclosureSEC source: 0001127602-18-010587 · form4.xml · nonDerivative · entry 19 Girshick Birgit · CIK 0001732091 · Corporate Executive VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,677 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.